Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMT-116 CAR-T
- Development stage
- Unknown
- Lead developer
- Multitude Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
AMT-116 CAR-T is an autologous chimeric antigen receptor T cell therapy designed for the treatment of advanced solid tumors[3][5][6][7]. It works by genetically engineering a patient’s own T lymphocytes to express chimeric antigen receptors, enhancing their ability to recognize and kill tumor cells through immunologic cytotoxicity and providing T lymphocyte replacements[3][5]. The drug is being evaluated in phase 1/2 clinical trials for use in advanced solid tumors, including non-small cell lung carcinoma and squamous cell cancer of the head and neck[3][6][7]. AMT-116 CAR-T represents a gene therapy and immunotherapy modality focused on the direct targeting and elimination of cancer cells[5].
- Brand names
- AMT-116 CAR-TAMT116 CAR-TAMT 116 CAR-T
- Other names
- AMT-116 CAR-TAMT116 CAR-TAMT 116 CAR-TAMT-116AMT116AMT 116
02
Targets
CD44v9 (CD44 variant 9)
Beyond the preview
Go deeper on AMT-116 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMT-116 CAR-T.